- Home
- EHAB vs ZBIO Comparison
EHAB vs ZBIO Comparison
Compare EHAB & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHAB
- ZBIO
- Stock Information
- Founded
- EHAB 2014
- ZBIO 2019
- Country
- EHAB United States
- ZBIO United States
- Employees
- EHAB N/A
- ZBIO N/A
- Industry
- EHAB Hospital/Nursing Management
- ZBIO
- Sector
- EHAB Health Care
- ZBIO
- Exchange
- EHAB Nasdaq
- ZBIO NYSE
- Market Cap
- EHAB 401.8M
- ZBIO 339.3M
- IPO Year
- EHAB N/A
- ZBIO 2024
- Fundamental
- Price
- EHAB $7.98
- ZBIO $7.85
- Analyst Decision
- EHAB Hold
- ZBIO Strong Buy
- Analyst Count
- EHAB 6
- ZBIO 5
- Target Price
- EHAB $9.20
- ZBIO $31.75
- AVG Volume (30 Days)
- EHAB 285.2K
- ZBIO 390.2K
- Earning Date
- EHAB 03-05-2025
- ZBIO 02-16-2025
- Dividend Yield
- EHAB N/A
- ZBIO N/A
- EPS Growth
- EHAB N/A
- ZBIO N/A
- EPS
- EHAB N/A
- ZBIO N/A
- Revenue
- EHAB $1,037,200,000.00
- ZBIO N/A
- Revenue This Year
- EHAB $0.93
- ZBIO N/A
- Revenue Next Year
- EHAB $3.50
- ZBIO N/A
- P/E Ratio
- EHAB N/A
- ZBIO N/A
- Revenue Growth
- EHAB N/A
- ZBIO N/A
- 52 Week Low
- EHAB $6.85
- ZBIO $7.50
- 52 Week High
- EHAB $11.74
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- EHAB 55.09
- ZBIO N/A
- Support Level
- EHAB $7.51
- ZBIO N/A
- Resistance Level
- EHAB $7.80
- ZBIO N/A
- Average True Range (ATR)
- EHAB 0.28
- ZBIO 0.00
- MACD
- EHAB 0.02
- ZBIO 0.00
- Stochastic Oscillator
- EHAB 83.19
- ZBIO 0.00
About EHAB Enhabit Inc.
Enhabit Inc provides home health and hospice services in the United States. It offers care where patients prefer it: in their homes. It operates business in two segments: home health and hospice. Its home health segment include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The hospice segment focuses on the quality of life for patients who are experiencing an advanced, life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates the majority of its revenue from the Home Health segment.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.